MN-TENNANT-COMPANY
Tennant Company (NYSE: TNC), a world leader in the design, manufacturing, and marketing of solutions to reinvent how the world cleans, and Brain Corp, a leading autonomous technology company creating transformative solutions in robotics and artificial intelligence (“AI”), jointly announce an exclusive technology agreement to accelerate the development and adoption of the next generation of robots in the floor-cleaning industry. This landmark agreement builds on the historically successful partnership between the two companies and seeks to accelerate innovation. Tennant and Brain Corp bring complementary strengths to the relationship that create an exceptional customer support ecosystem. Tennant has a 150-plus year history of building industry-leading cleaning equipment and has expansive direct sales and service coverage. Brain Corp offers industry-leading and AI-enabled AMR cleaning technology, with more than 6,500 Tennant cleaning robots in the field powered by Brain. We expect Tennant’s purpose-built robotic equipment driven by Brain Corp’s next-generation and AI-enabled autonomous navigation technology will improve the customer return on investment and enable more customers to invest in robotic cleaning.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240222888342/en/
“Our customers have always relied on Tennant for equipment innovation and aftermarket support to address key business challenges such as labor shortages and cost pressures,” said Tennant Company President and CEO Dave Huml. “Our partnership with Brain Corp has already produced an industry-leading portfolio of autonomous equipment in this fast-growing space. We are excited to expand our existing partnership to dramatically accelerate the transition to robotic cleaning and drive adoption in new segments of our markets. By combining cleaning intelligence and automation, we are poised to lead the disruption that AI-enabled robotic technology will bring to our industry.”
In the second quarter of 2024, Tennant will launch the new X4 ROVR, the company’s first purpose-built Autonomous Mobile Robot (AMR). The X4 ROVR offers greater maneuverability, is specifically designed for operation in smaller spaces, and is driven by Brain Corp’s next-generation navigation software and hardware suite which will be available exclusively on Tennant machines for floorcare applications. Its compact size, improved obstacle detection, and enhanced mobility will result in fewer assists and deliver a step-change improvement in customer ROI. The X4 ROVR is expected to drive an increase in robotic cleaning adoption as it provides an on-ramp to customers for whom robotic technology has previously been out of reach. The X4 ROVR is the first of many planned future AMR cleaning products powered by Brain Corp’s next-generation technology that will be exclusively available on Tennant equipment. With this agreement, the partnership seeks to accelerate the build-out of a portfolio of robotic floor-cleaning solutions to cover more cleaning applications and enhance customers’ return on investment to drive adoption.
Tennant and Brain Corp bring complementary strengths to the partnership that are positioned to drive an acceleration of robotic cleaning adoption. Tennant has a 150-plus year history of building exceptional cleaning equipment, a strong go-to-market strategy, and a differentiated customer support ecosystem. Brain Corp offers industry-leading and AI-enabled AMR cleaning technology, with more than 6,500 Tennant cleaning robots in the field powered by BrainOS®.
With this agreement and starting with the X4 ROVR, Tennant will begin offering an all-in-one AMR solution, with the equipment and autonomy services bundled as a single solution sold by Tennant. This new approach will simplify the buying experience for customers and result in Tennant benefiting from recurring revenue for autonomy services moving forward.
“This partnership further aligns two companies driven by a shared purpose: to elevate productivity and efficiency, and provide essential support for janitorial teams facing understaffing and overwhelming demand,” said Brain Corp CEO David Pinn. “At Brain Corp, we envision a world where people’s lives are made safer, easier, more productive, and more fulfilling with the help of robots, and I believe this expanded partnership will supercharge this into reality.”
“Innovation and customer focus are a significant part of Tennant’s identity,” said Huml. “This partnership amplifies our commitment to innovation as well as Brain Corp’s position as a pioneer in AI and automation applied to cleaning equipment. We are excited to unlock the full potential of next-generation robotic floor cleaning solutions that deliver true business value to customers who use our AMR equipment today and those who are waiting eagerly for an AMR solution that they can leverage for their businesses.”
With this agreement, Tennant invested $32 million in Brain Corp and Fay West, Tennant Company Senior Vice President and Chief Financial Officer, will join the Brain Corp board of directors.
About Tennant
Founded in 1870, Tennant Company (NYSE: TNC), headquartered in Eden Prairie, Minnesota, is a world leader in the design, manufacture and marketing of solutions that help create a cleaner, safer and healthier world. Its innovative products include equipment for maintaining surfaces in industrial, commercial and outdoor environments; detergent-free and other sustainable cleaning technologies; and cleaning tools and supplies. Tennant's global field service network is the most extensive in the industry. Tennant Company had sales of $1.24 billion in 2023 and has approximately 4,457 employees. Tennant has manufacturing operations throughout the world and sells products directly in 15 countries and through distributors in more than 100 countries. For more information, visit www.tennantco.com and www.ipcworldwide.com.
About Brain Corp
Brain Corp is the global leader in robotic AI software that powers the largest fleet of autonomous mobile robots (AMRs) operating in commercial public spaces. Global OEM partners use the company's cloud-connected platform, BrainOS®, to create scalable, self-driving robots that are used by end customers to clean floors and sense environmental data - turning manual operations into automated workflows. Fortune 500 brands across multiple verticals benefit from the growing portfolio of BrainOS®-powered robots and our industry-leading privacy, safety and efficiency tools that make managing and scaling automation easier. Brain Corp currently powers more than 30,000 AMRs, representing the largest fleet of its kind in the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222888342/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom